Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Adjuvant Chemotherapy Does Not Significantly Increase Breast Cancer-Related Lymphedema Risk

      December 13, 2022
      By Lindsay Fischer
      Article
      Conferences|San Antonio Breast Cancer Symposium

      Treatment with chemotherapy, including taxane-based chemotherapies, in the adjuvant setting did not yield significant differences in breast-cancer related lymphedema risk.

      Amanda W. Jung, MPH

      Amanda W. Jung, MPH

      Adjuvant chemotherapy, including taxane-based chemotherapy, was not associated with a significant increase in risk of breast-cancer related lymphedema (BCRL), according to a poster presentation from the 2022 San Antonio Breast Cancer Symposium.1

      At a median follow-up of 58 months, a total of 141 patients (8%) out of an evaluable 1759 developed BCRL. The median time between surgery and BRCL development was 21 months. Factors determined to contribute to a significant increase in BCRL risk were age (65 years or older at the time of diagnosis; P < .001) and having a body mass index (BMI) equal to or greater than 30 (P = .005).

      Compared with no chemotherapy treatment, neither taxane-based chemotherapies (P = .97) nor nontaxane based chemotherapies (P = .58) showed significant differences in BCRL risk. In addition, there were no significant differences in BCRL risk between taxane and nontaxane based therapies (P = .55).

      Axillary lymph node dissection (ALND) with or without regional lymph node radiation (RLNR) was found to yield a significant increase in risk of BCRL compared with no nodal surgery (P < .001).

      “[These] findings will improve patient education on BCRL risk for those receiving adjuvant chemotherapy, specifically for taxane-based chemotherapy,” Amanda W. Jung, MPH, of the Lymphedema Research Program in the Department of Radiation Oncology at Massachusetts General Hospital, and coinvestigators, wrote in the poster.

      Taxane-based chemotherapies are commonly associated with fluid retention in the extremities, which may raise the risk of BCRL for patients. However, evidence surrounding the impact of adjuvant chemotherapy and taxane-based chemotherapy on BCRL are often inhibited by methodological flaws, according to the study authors. Therefore, they sought to determine if adjuvant chemotherapy represented an independent risk factor of BCRL. Additionally, investigators assessed whether taxane-based chemotherapies showed a significant difference in elevating the risk of this toxicity.

      The study screened patients being treated for breast cancer using perometry to measure their overall limb volume at a preoperative baseline.1,2 Patients needed to have had their arm measurements obtained at diagnosis of metastatic disease and before their bilateral breast cancer surgery. If obtained later than these time points, they could not be included. In addition, patients who had received neoadjuvant chemotherapy were not included.1

      Investigators defined BCRL as a relative volume change of 10% or greater between their measurements before surgery and their measurement 3 months following surgery. A cox regression model was used to estimate adjusted hazard ratios. Findings were adjusted for baseline BMI, ALND, RLNR, age at time of diagnosis, and smoking history.

      Of the 1759 patients included in the analysis, 506 (29%) were 65 years or older. These patients accounted for 26% (n = 27) of the adjuvant nontaxane chemotherapy cohort (n = 104), 15% (n = 84) of the taxane-based cohort (n = 564), and 36% (n = 395) of the no chemotherapy cohort (n = 1091).

      A total of 503 study participants overall (29%) had a BMI greater than 30, including 20 patients (19%) in the nontaxane chemotherapy group, 158 patients (28%) in the taxane-based chemotherapy group, and 325 patients (30%) in the no chemotherapy group.

      In the total population, 93 patients who underwent both ALND and RLNR (5.3%), this included 3 patients (2.9%) in the nontaxane group, 5 patients (0.9%) in the taxane-based group, and 85 patients (7.8%) in the no chemotherapy group. Additionally, the percentage of patients who received ALND without RLNR was 11% (n = 201), including 11% (n = 11), 29% (n = 166), and 2.2% (n = 24) of the taxane, nontaxane, and no chemotherapy groups, respectively.

      “Receipt of adjuvant chemotherapy and specifically adjuvant taxane-based chemotherapy were not associated with increased risk of BCRL,” study authors concluded. “ALND, RLNR, and high baseline BMI remained independent risk factors for BCRL.”

      References

      1. Jung AW, Juel BC, Smith LS, et al. The impact of adjuvant chemotherapy, including taxanes, on breast cancer-related lymphedema risk. Presented at 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX. Abstract P1-12-05.

      2. Dylke ES, Ward LC, Kilbreath SL. Standardized approach to lymphedema screening. Oncologist. 2013;18(11):1242. doi:10.1634/theoncologist.2013-0238

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
      Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
      Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
      Image of a woman with white hair in front of an Oncology Nursing News blue background
      Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop
      Image of a woman with shoulder-length black hair wearing headphones and a white sweater
      Photo of a woman with brown hair and bangs, surrounded by a blue border
      Image of a woman with a white shirt in front of an Oncology Nursing News branded backdrop
      Photo of a man with glasses in a suit in front of an Oncology Nursing News backdrop
      Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
      Related Content

      Graphic of a breast with a tumor

      T-DXd Regimen Improves pCR in Early HER2+ Breast Cancer

      Sabrina Serani
      May 13th 2025
      Article

      T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.


      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      October 2nd 2023
      Podcast

      Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.


      Image of red blood cells

      Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma

      Ashling Wahner
      April 22nd 2025
      Article

      Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer

      Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer

      Lindsay Fischer
      April 3rd 2023
      Podcast

      Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.


      Image of blood with leukemia cells present

      Variability Found in PROs, Gene Expression During AML Induction Chemo

      Chris Ryan
      April 21st 2025
      Article

      Gene expression in peripheral blood as well as patient-reported outcomes differed for those with acute myeloid leukemia undergoing induction chemotherapy.


      Line illustration of red blood cells on a yellow background

      Blinatumomab-Linked ICANS Cases Higher Than Previously Reported

      Russ Conroy
      April 20th 2025
      Article

      Using tools like the ICE Score could improve consistency in grading neurotoxicity tied to bispecific antibodies in hematologic cancers.

      Related Content

      Graphic of a breast with a tumor

      T-DXd Regimen Improves pCR in Early HER2+ Breast Cancer

      Sabrina Serani
      May 13th 2025
      Article

      T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.


      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      October 2nd 2023
      Podcast

      Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.


      Image of red blood cells

      Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma

      Ashling Wahner
      April 22nd 2025
      Article

      Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer

      Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer

      Lindsay Fischer
      April 3rd 2023
      Podcast

      Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.


      Image of blood with leukemia cells present

      Variability Found in PROs, Gene Expression During AML Induction Chemo

      Chris Ryan
      April 21st 2025
      Article

      Gene expression in peripheral blood as well as patient-reported outcomes differed for those with acute myeloid leukemia undergoing induction chemotherapy.


      Line illustration of red blood cells on a yellow background

      Blinatumomab-Linked ICANS Cases Higher Than Previously Reported

      Russ Conroy
      April 20th 2025
      Article

      Using tools like the ICE Score could improve consistency in grading neurotoxicity tied to bispecific antibodies in hematologic cancers.

      Latest Conference Coverage

      Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma

      Acupuncture Use in BC Predicted by Social Determinants of Health

      Variability Found in PROs, Gene Expression During AML Induction Chemo

      Blinatumomab-Linked ICANS Cases Higher Than Previously Reported

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.